Bladder Cancer, Urothelial Carcinoma News Articles

Bladder Cancer News

BLADDER CANCER ADVISOR

Bladder Cancer News

cystectomy

Bladder Cancer Surgery Safe Following Neoadjuvant Immunotherapy

Toxicity profile and readmission rates among patients who underwent radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab are in line with previously published series reporting 90-day outcomes after RC with or without neoadjuvant chemotherapy.

Keytruda Approved for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer

The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
kidney cross section

Preoperative Pyuria Predicts Bladder Recurrence After UTUC Surgery

In a small study of patients without a history of bladder cancer who undergo radical nephroureterectomy for upper tract urothelial carcinoma, preoperative pyuria was associated with a 1.7-fold increased risk of intravesical recurrence, a study found.
mri, bladder cancer, mri scan, bladder scan, urology, nephrology, aua 2017

NAC Increases Pathologic Complete Response Rate in High-Risk MIBC

In a study of patients with high-risk muscle-invasive bladder cancer, patients who received cisplatin-based neoadjuvant chemotherapy had a 3.6 times higher rate of pathologic complete response compared with those who had upfront radical cystectomy.